ALEKSANDRA GOLDEN: Open Payments
NPI 1982201901 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,386 in 74 payments from 12 companies in 2025. Trend: 2023 $595 · 2024 $1,231 · 2025 $1,386
Food & beverage: $1,386
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $288 |
| AstraZeneca Pharmaceuticals LP | 9 | $264 |
| ABBVIE INC. | 20 | $258 |
| Astellas Pharma US Inc | 5 | $155 |
| PFIZER INC. | 6 | $116 |
| Lilly USA, LLC | 5 | $82 |
| Gilead Sciences, Inc. | 3 | $81 |
| Abbott Laboratories | 2 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $44 |
| ViiV Healthcare Company | 1 | $18 |
Products named: AIRSUPRA, Wegovy, Veozah, Ozempic, VRAYLAR, UBRELVY, PREVNAR 20, MOUNJARO.
Industry payments across TX — which companies pay providers there.
